Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-5-3
pubmed:abstractText
Vinorelbine is currently one of the most active chemotherapeutic agents. However, it is also a moderate vesicant that is well known to cause venous irritation and phlebitis. We conducted this study to identify clinical risk factors related to the incidence of venous irritation caused by peripheral vinorelbine infusion.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0368-2811
pubmed:author
pubmed:issnType
Print
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
206-9
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:15121757-Adult, pubmed-meshheading:15121757-Aged, pubmed-meshheading:15121757-Aged, 80 and over, pubmed-meshheading:15121757-Antineoplastic Agents, Phytogenic, pubmed-meshheading:15121757-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15121757-Body Mass Index, pubmed-meshheading:15121757-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:15121757-Cisplatin, pubmed-meshheading:15121757-Deoxycytidine, pubmed-meshheading:15121757-Female, pubmed-meshheading:15121757-Humans, pubmed-meshheading:15121757-Infusions, Intravenous, pubmed-meshheading:15121757-Lung Neoplasms, pubmed-meshheading:15121757-Male, pubmed-meshheading:15121757-Middle Aged, pubmed-meshheading:15121757-Mitomycins, pubmed-meshheading:15121757-Phlebitis, pubmed-meshheading:15121757-Retrospective Studies, pubmed-meshheading:15121757-Risk Factors, pubmed-meshheading:15121757-Vinblastine
pubmed:year
2004
pubmed:articleTitle
High body mass index correlates with increased risk of venous irritation by vinorelbine infusion.
pubmed:affiliation
Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. kyoh@east.ncc.go.jp
pubmed:publicationType
Journal Article